Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Affluent Partners Holdings ( (HK:1466) ).
Baijin Life Science Holdings Limited announced its interim results for the six months ended 30 September 2025, reporting a revenue of HK$55,145,000, a decrease from the previous year’s HK$70,900,000. Despite the drop in revenue, the company achieved a profit of HK$2,517,000, a significant improvement from a loss of HK$1,901,000 in the same period last year, indicating a positive shift in financial performance.
The most recent analyst rating on (HK:1466) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.
More about Affluent Partners Holdings
Baijin Life Science Holdings Limited, formerly known as Affluent Partners Holdings Limited, operates in the life sciences industry. The company is incorporated in the Cayman Islands and focuses on providing scientific solutions and services.
Average Trading Volume: 441,966
Technical Sentiment Signal: Hold
Current Market Cap: HK$526.4M
For detailed information about 1466 stock, go to TipRanks’ Stock Analysis page.